159 related articles for article (PubMed ID: 12065742)
1. (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase.
Beck G; Bottomley G; Bradshaw D; Brewster M; Broadhurst M; Devos R; Hill C; Johnson W; Kim HJ; Kirtland S; Kneer J; Lad N; Mackenzie R; Martin R; Nixon J; Price G; Rodwell A; Rose F; Tang JP; Walter DS; Wilson K; Worth E
J Pharmacol Exp Ther; 2002 Jul; 302(1):390-6. PubMed ID: 12065742
[TBL] [Abstract][Full Text] [Related]
2. Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme.
Zhang Y; Hegen M; Xu J; Keith JC; Jin G; Du X; Cummons T; Sheppard BJ; Sun L; Zhu Y; Rao VR; Wang Q; Xu W; Cowling R; Nickerson-Nutter CL; Gibbons J; Skotnicki J; Lin LL; Levin J
Int Immunopharmacol; 2004 Dec; 4(14):1845-57. PubMed ID: 15531300
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL
J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.
Xue CB; Voss ME; Nelson DJ; Duan JJ; Cherney RJ; Jacobson IC; He X; Roderick J; Chen L; Corbett RL; Wang L; Meyer DT; Kennedy K; DeGradodagger WF; Hardman KD; Teleha CA; Jaffee BD; Liu RQ; Copeland RA; Covington MB; Christ DD; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
J Med Chem; 2001 Aug; 44(16):2636-60. PubMed ID: 11472217
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases.
Conway JG; Andrews RC; Beaudet B; Bickett DM; Boncek V; Brodie TA; Clark RL; Crumrine RC; Leenitzer MA; McDougald DL; Han B; Hedeen K; Lin P; Milla M; Moss M; Pink H; Rabinowitz MH; Tippin T; Scates PW; Selph J; Stimpson SA; Warner J; Becherer JD
J Pharmacol Exp Ther; 2001 Sep; 298(3):900-8. PubMed ID: 11504783
[TBL] [Abstract][Full Text] [Related]
6. Unlike for human monocytes after LPS activation, release of TNF-α by THP-1 cells is produced by a TACE catalytically different from constitutive TACE.
Moreira-Tabaka H; Peluso J; Vonesch JL; Hentsch D; Kessler P; Reimund JM; Dumont S; Muller CD
PLoS One; 2012; 7(3):e34184. PubMed ID: 22479555
[TBL] [Abstract][Full Text] [Related]
7. Reverse hydroxamate-based selective TACE inhibitors.
Kamei N; Tanaka T; Kawai K; Miyawaki K; Okuyama A; Murakami Y; Arakawa Y; Haino M; Harada T; Shimano M
Bioorg Med Chem Lett; 2004 Jun; 14(11):2897-900. PubMed ID: 15125955
[TBL] [Abstract][Full Text] [Related]
8. Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.
Holms J; Mast K; Marcotte P; Elmore I; Li J; Pease L; Glaser K; Morgan D; Michaelides M; Davidsen S
Bioorg Med Chem Lett; 2001 Nov; 11(22):2907-10. PubMed ID: 11677124
[TBL] [Abstract][Full Text] [Related]
9. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
Levin JI; Du MT
Drug Des Discov; 2003; 18(4):123-6. PubMed ID: 15553924
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humans.
Qian M; Bai SA; Brogdon B; Wu JT; Liu RQ; Covington MB; Vaddi K; Newton RC; Fossler MJ; Garner CE; Deng Y; Maduskuie T; Trzaskos J; Duan JJ; Decicco CP; Christ DD
Drug Metab Dispos; 2007 Oct; 35(10):1916-25. PubMed ID: 17656469
[TBL] [Abstract][Full Text] [Related]
11. New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.
Barlaam B; Bird TG; Lambert-Van Der Brempt C; Campbell D; Foster SJ; Maciewicz R
J Med Chem; 1999 Nov; 42(23):4890-908. PubMed ID: 10579851
[TBL] [Abstract][Full Text] [Related]
12. TACE/ADAM17-TNF-alpha pathway in rat cortical cultures after exposure to oxygen-glucose deprivation or glutamate.
Hurtado O; Lizasoain I; Fernández-Tomé P; Alvarez-Barrientos A; Leza JC; Lorenzo P; Moro MA
J Cereb Blood Flow Metab; 2002 May; 22(5):576-85. PubMed ID: 11973430
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of TNF-alpha convertase (TACE/ADAM17) after oxygen-glucose deprivation in rat forebrain slices.
Hurtado O; Cárdenas A; Lizasoain I; Boscá L; Leza JC; Lorenzo P; Moro MA
Neuropharmacology; 2001 Jun; 40(8):1094-102. PubMed ID: 11406201
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.
Cherney RJ; Duan JJ; Voss ME; Chen L; Wang L; Meyer DT; Wasserman ZR; Hardman KD; Liu RQ; Covington MB; Qian M; Mandlekar S; Christ DD; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
J Med Chem; 2003 May; 46(10):1811-23. PubMed ID: 12723945
[TBL] [Abstract][Full Text] [Related]
15. In vitro ischemic tolerance involves upregulation of glutamate transport partly mediated by the TACE/ADAM17-tumor necrosis factor-alpha pathway.
Romera C; Hurtado O; Botella SH; Lizasoain I; Cárdenas A; Fernández-Tomé P; Leza JC; Lorenzo P; Moro MA
J Neurosci; 2004 Feb; 24(6):1350-7. PubMed ID: 14960606
[TBL] [Abstract][Full Text] [Related]
16. Biology of TACE inhibition.
Newton RC; Solomon KA; Covington MB; Decicco CP; Haley PJ; Friedman SM; Vaddi K
Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii25-32. PubMed ID: 11890648
[TBL] [Abstract][Full Text] [Related]
17. Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.
Kottirsch G; Koch G; Feifel R; Neumann U
J Med Chem; 2002 May; 45(11):2289-93. PubMed ID: 12014967
[TBL] [Abstract][Full Text] [Related]
18. Differential effects between marimastat, a TNF-alpha converting enzyme inhibitor, and anti-TNF-alpha antibody on murine models for sepsis and arthritis.
Tsuji F; Oki K; Okahara A; Suhara H; Yamanouchi T; Sasano M; Mita S; Horiuchi M
Cytokine; 2002 Mar; 17(6):294-300. PubMed ID: 12061836
[TBL] [Abstract][Full Text] [Related]
19. Benzodiazepine inhibitors of the MMPs and TACE. Part 2.
Levin JI; Nelson FC; Delos Santos E; Du MT; MacEwan G; Chen JM; Ayral-Kaloustian S; Xu J; Jin G; Cummons T; Barone D
Bioorg Med Chem Lett; 2004 Aug; 14(16):4147-51. PubMed ID: 15261259
[TBL] [Abstract][Full Text] [Related]
20. Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents.
Lu Z; Ott GR; Anand R; Liu RQ; Covington MB; Vaddi K; Qian M; Newton RC; Christ DD; Trzaskos J; Duan JJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):1958-62. PubMed ID: 18282708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
